A detailed history of Castleark Management LLC transactions in Glaukos Corp stock. As of the latest transaction made, Castleark Management LLC holds 73,830 shares of GKOS stock, worth $11.1 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
73,830
Previous 74,470 0.86%
Holding current value
$11.1 Million
Previous $8.81 Million 9.13%
% of portfolio
0.4%
Previous 0.37%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$113.62 - $135.39 $72,716 - $86,649
-640 Reduced 0.86%
73,830 $9.62 Million
Q2 2024

Aug 13, 2024

BUY
$89.48 - $118.35 $855,428 - $1.13 Million
9,560 Added 14.73%
74,470 $8.81 Million
Q1 2024

May 15, 2024

SELL
$76.4 - $96.33 $202,460 - $255,274
-2,650 Reduced 3.92%
64,910 $6.12 Million
Q4 2023

Feb 14, 2024

SELL
$59.53 - $85.11 $283,362 - $405,123
-4,760 Reduced 6.58%
67,560 $5.37 Million
Q3 2023

Nov 15, 2023

BUY
$69.23 - $79.09 $5.01 Million - $5.72 Million
72,320 New
72,320 $5.44 Million
Q3 2022

Nov 15, 2022

SELL
$46.84 - $58.49 $58,550 - $73,112
-1,250 Reduced 2.26%
54,150 $2.88 Million
Q2 2022

Aug 16, 2022

SELL
$34.86 - $63.77 $329,078 - $601,988
-9,440 Reduced 14.56%
55,400 $2.52 Million
Q1 2022

May 16, 2022

BUY
$44.33 - $57.82 $2.87 Million - $3.75 Million
64,840 New
64,840 $3.75 Million
Q3 2021

Nov 12, 2021

SELL
$47.43 - $84.23 $1.75 Million - $3.11 Million
-36,900 Closed
0 $0
Q2 2021

Aug 17, 2021

BUY
$73.06 - $97.7 $2.7 Million - $3.61 Million
36,900 New
36,900 $3.13 Million
Q3 2019

Nov 15, 2019

SELL
$58.58 - $83.91 $7.77 Million - $11.1 Million
-132,645 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$63.59 - $78.71 $693,766 - $858,726
10,910 Added 8.96%
132,645 $10 Million
Q1 2019

May 14, 2019

BUY
$50.75 - $80.54 $6.18 Million - $9.8 Million
121,735 New
121,735 $9.54 Million

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $7.18B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Castleark Management LLC Portfolio

Follow Castleark Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castleark Management LLC with notifications on news.